Literature DB >> 18551609

Substitution of amino acid 70 in the hepatitis C virus core region of genotype 1b is an important predictor of elevated alpha-fetoprotein in patients without hepatocellular carcinoma.

Norio Akuta1, Fumitaka Suzuki, Yusuke Kawamura, Hiromi Yatsuji, Hitomi Sezaki, Yoshiyuki Suzuki, Tetsuya Hosaka, Masahiro Kobayashi, Mariko Kobayashi, Yasuji Arase, Kenji Ikeda, Hiromitsu Kumada.   

Abstract

Previous studies identified amino acid (aa) substitutions of the hepatitis C virus core region of genotype 1b (HCV-1b core region) and elevated serum alpha-fetoprotein (AFP) levels as predictors of poor virologic response to pegylated interferon (PEG-IFN) plus ribavirin (RBV), and also as risk factors for hepatocarcinogenesis. The present study evaluated the impact of aa substitutions of HCV-1b core region on AFP, as a surrogate marker of hepatocarcinogenesis, on AFP levels in 569 Japanese patients with HCV-1b but without HCC, and investigated the predictive factors of elevated AFP (> or =11 microg/L). High AFP levels were detected in 27.4% of the patients. The rate of hepatocarcinogenesis in a group of 109 patients who received IFN monotherapy and followed-up for 15 years, was significantly higher in patients with abnormal than normal AFP. Multivariate analysis of 569 patients identified fibrosis stage (F3,4), aspartate aminotransferase (> or =76 IU/L), substitution of aa 70 (glutamine or histidine), and platelet count (<15.0 x 10(4)/microl) as significant determinants of elevated AFP. In 49 patients with abnormal AFP levels and substitutions at aa 70 who were treated with PEG-IFN + RBV, the rate of normalization of AFP was significantly lower in non-virological responders (28.6%) than in transient (71.4%) and sustained (100%) virological responders. The results indicated that substitution of aa 70 of HCV-1b core region is an important predictor of elevated AFP in non-HCC patients, and that eradication of the mutant virus normalizes AFP. The results highlight the importance of eradication of mutant type virus of aa 70 for reducing the risk of hepatocarcinogenesis.

Entities:  

Mesh:

Substances:

Year:  2008        PMID: 18551609     DOI: 10.1002/jmv.21202

Source DB:  PubMed          Journal:  J Med Virol        ISSN: 0146-6615            Impact factor:   2.327


  8 in total

1.  Hepatitis C virus Genotype 1a core gene nucleotide patterns associated with hepatocellular carcinoma risk.

Authors:  Brent Korba; Kirti Shetty; Alexei Medvedev; Prasanth Viswanathan; Rency Varghese; Bin Zhou; Rabindra Roy; Kepher Makambi; Habtom Ressom; Christopher A Loffredo
Journal:  J Gen Virol       Date:  2015-07-03       Impact factor: 3.891

Review 2.  Hepatitis C virus induced insulin resistance impairs response to anti viral therapy.

Authors:  Abdel-Rahman El-Zayadi; Mahmoud Anis
Journal:  World J Gastroenterol       Date:  2012-01-21       Impact factor: 5.742

3.  Analysis of viral amino acids sequences and the IL28B SNP influencing the development of hepatocellular carcinoma in chronic hepatitis C.

Authors:  Mika Miura; Shinya Maekawa; Makoto Kadokura; Ryota Sueki; Kazuki Komase; Hiroko Shindo; Takako Ohmori; Asuka Kanayama; Kuniaki Shindo; Fumitake Amemiya; Yasuhiro Nakayama; Takatoshi Kitamura; Tomoyoshi Uetake; Taisuke Inoue; Minoru Sakamoto; Shunichi Okada; Nobuyuki Enomoto
Journal:  Hepatol Int       Date:  2011-08-17       Impact factor: 6.047

Review 4.  Hepatitis C virus molecular evolution: transmission, disease progression and antiviral therapy.

Authors:  Maria Victoria Preciado; Pamela Valva; Alejandro Escobar-Gutierrez; Paula Rahal; Karina Ruiz-Tovar; Lilian Yamasaki; Carlos Vazquez-Chacon; Armando Martinez-Guarneros; Juan Carlos Carpio-Pedroza; Salvador Fonseca-Coronado; Mayra Cruz-Rivera
Journal:  World J Gastroenterol       Date:  2014-11-21       Impact factor: 5.742

Review 5.  Viral factors influencing the response to the combination therapy of peginterferon plus ribavirin in chronic hepatitis C.

Authors:  Shinya Maekawa; Nobuyuki Enomoto
Journal:  J Gastroenterol       Date:  2009       Impact factor: 7.527

6.  Silencing of microRNA-122 enhances interferon-α signaling in the liver through regulating SOCS3 promoter methylation.

Authors:  Takeshi Yoshikawa; Akemi Takata; Motoyuki Otsuka; Takahiro Kishikawa; Kentaro Kojima; Haruhiko Yoshida; Kazuhiko Koike
Journal:  Sci Rep       Date:  2012-09-06       Impact factor: 4.379

7.  Evaluation of Interferon Resistance in Newly Established Genotype 1b Hepatitis C Virus Cell Culture System.

Authors:  Miki Taniguchi; Megumi Tasaka-Fujita; Mina Nakagawa; Takako Watanabe; Fukiko Kawai-Kitahata; Satoshi Otani; Fumio Goto; Hiroko Nagata; Shun Kaneko; Sayuri Nitta; Miyako Murakawa; Yuki Nishimura-Sakurai; Seishin Azuma; Yasuhiro Itsui; Kenichi Mori; Shintaro Yagi; Sei Kakinuma; Yasuhiro Asahina; Mamoru Watanabe
Journal:  J Clin Transl Hepatol       Date:  2016-03-15

8.  Improved Serum Alpha-Fetoprotein Levels after Iron Reduction Therapy in HCV Patients.

Authors:  Hidenao Noritake; Yoshimasa Kobayashi; Yukimasa Ooba; Kensuke Kitsugi; Shin Shimoyama; Satoru Yamazaki; Takeshi Chida; Shinya Watanabe; Kazuhito Kawata; Takafumi Suda
Journal:  ISRN Hepatol       Date:  2014-02-04
  8 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.